X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (85) 85
humans (80) 80
melanoma (71) 71
immunotherapy (54) 54
oncology (52) 52
cancer (50) 50
article (42) 42
ipilimumab (41) 41
female (37) 37
male (34) 34
melanoma - drug therapy (32) 32
animals (31) 31
antibodies, monoclonal - therapeutic use (31) 31
metastatic melanoma (31) 31
tumors (28) 28
immunology (27) 27
aged (26) 26
middle aged (26) 26
melanoma - immunology (25) 25
lymphocytes (24) 24
t cells (23) 23
adult (22) 22
care and treatment (21) 21
aged, 80 and over (20) 20
mice (20) 20
melanoma - pathology (19) 19
research (19) 19
metastasis (18) 18
ctla-4 (17) 17
skin neoplasms - drug therapy (17) 17
antigens (16) 16
ctla-4 blockade (16) 16
immune response (16) 16
malignant-melanoma (16) 16
patients (16) 16
antibodies, monoclonal - adverse effects (15) 15
medical research (15) 15
mice, inbred c57bl (15) 15
neoplasms - immunology (15) 15
survival (15) 15
abridged index medicus (14) 14
antineoplastic agents - therapeutic use (14) 14
drug therapy (14) 14
lymphocytes t (14) 14
neoplasms - therapy (14) 14
analysis (13) 13
cd8-positive t-lymphocytes - immunology (13) 13
health aspects (13) 13
mutation (13) 13
skin neoplasms - pathology (13) 13
antibodies (12) 12
antigens, neoplasm - immunology (12) 12
cell biology (12) 12
clinical trials (12) 12
expression (12) 12
medicine, research & experimental (12) 12
neoplasm staging (12) 12
treatment outcome (12) 12
vaccination (12) 12
antitumor immunity (11) 11
chemotherapy (11) 11
dendritic cells (11) 11
immunotherapy - methods (11) 11
therapy (11) 11
vaccines (11) 11
antibodies, monoclonal - administration & dosage (10) 10
antineoplastic agents - adverse effects (10) 10
immune system (10) 10
medicine & public health (10) 10
medicine, general & internal (10) 10
melanoma - therapy (10) 10
monoclonal antibodies (10) 10
open-label (10) 10
research article (10) 10
t-cells (10) 10
antibody (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
cancer therapies (9) 9
disease progression (9) 9
immunity (9) 9
metastases (9) 9
multidisciplinary sciences (9) 9
proteins (9) 9
studies (9) 9
t cell receptors (9) 9
trial (9) 9
biology (8) 8
cancer vaccines (8) 8
cancer vaccines - immunology (8) 8
ctla-4 antigen (8) 8
ctla-4 antigen - immunology (8) 8
cytotoxicity (8) 8
development and progression (8) 8
dosage and administration (8) 8
double-blind (8) 8
in-vivo (8) 8
medicine (8) 8
melanoma - mortality (8) 8
melanoma - secondary (8) 8
peptides (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 21, pp. 1976 - 1986
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2016, Volume 22, Issue 12, pp. 2908 - 2918
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 19, pp. 1845 - 1855
Journal Article
Cancer Discovery, ISSN 2159-8274, 07/2018, Volume 8, Issue 7, pp. 822 - 835
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct... 
CTLA-4 BLOCKADE | CANCER-PATIENTS | MELANOMA | ONCOLOGY | COOCCURRING GENOMIC ALTERATIONS | OPEN-LABEL | RANDOMIZED CONTROLLED-TRIAL | NIVOLUMAB | LKB1 LOSS | DOCETAXEL | TUMOR MICROENVIRONMENT | non-small cell lung cancer | PD-1 blockade | STK11 | KRAS | LKB1 | lung adenocarcinoma
Journal Article